marimastat has been researched along with Invasiveness, Neoplasm in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (23.08) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Hall, AR; Rajan, SAP; Skardal, A | 1 |
| Haage, A; Schneider, IC | 1 |
| Bian, H; Chen, ZN; Feng, F; Nan, G; Sun, XX; Wang, B; Wang, Y; Wei, D; Yang, XM; Yuan, L | 1 |
| Newton, HB | 1 |
| Bernardo, P; Davidson, NE; Gradishar, WJ; Ingle, JN; Sparano, JA; Stephenson, P; Zucker, S | 1 |
| Nakada, M | 1 |
| Sasaki, H; Yoshida, K | 1 |
| Dickson, RB; Hawkins, MJ; Wojtowicz-Praga, SM | 1 |
| Davidson, S | 1 |
| Bouterfa, H; Hanke, A; Kerkau, S; Mueller, JG; Roosen, K; Tonn, JC; Vince, GH; Wagner, S | 1 |
| Balduyck, M; Dacquembronne, E; Dejonghe, MJ; Duhem, T; Gouyer, V; Grard, G; Hemon, B; Huet, G; Lebrun, A; Lemaire, R; Lemaire, V; Thiebaut, C; Zerimech, F | 1 |
| Ichikawa, Y; Ishikawa, T; Shimada, H; Tanaka, K; Togo, S | 1 |
| Adachi, Y; Imai, K; Itoh, F | 1 |
6 review(s) available for marimastat and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 3: brain tumor invasiveness.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Extracellular Matrix; Gene Expression Profiling; Humans; Hydroxamic Acids; Matrix Metalloproteinases; Neoplasm Invasiveness; Quality of Life; Serine Endopeptidases; Survival | 2004 |
[Role of extracellular matrix degradation enzyme for glioma invasion].
Topics: ADAM Proteins; Brain Neoplasms; Dacarbazine; Drug Design; Enzyme Inhibitors; Extracellular Matrix; Glioma; Humans; Hydroxamic Acids; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Neoplasm Invasiveness; Serine Endopeptidases; Temozolomide; Tetracyclines | 2005 |
[Inhibition of cellular adhesion and invasion in gliomas].
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cathepsin B; Cell Adhesion; Clinical Trials as Topic; Drug Design; Extracellular Matrix; Glioma; Humans; Hyaluronan Receptors; Hyaluronic Acid; Hydroxamic Acids; Integrins; Laminin; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Multigene Family; Neoplasm Invasiveness; Signal Transduction; Snake Venoms; Urokinase-Type Plasminogen Activator | 2005 |
Matrix metalloproteinase inhibitors.
Topics: Antineoplastic Agents; Cell Division; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Down-Regulation; Drugs, Investigational; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Hydroxamic Acids; Metalloendopeptidases; Molecular Weight; Neoplasm Invasiveness; Neoplasms; Neovascularization, Pathologic; Phenylalanine; Protease Inhibitors; Protein Kinase C; Proteins; Thiophenes; Tissue Inhibitor of Metalloproteinase-2; Tissue Inhibitor of Metalloproteinase-3; Tissue Inhibitor of Metalloproteinases | 1997 |
[Extracellular matrix degradation enzymes: important factors in liver metastasis of colorectal cancer and good targets for anticancer metastatic therapy].
Topics: Colorectal Neoplasms; Enzyme Inhibitors; Extracellular Matrix; Humans; Hydroxamic Acids; Liver Neoplasms; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Neoplasm Invasiveness; Neovascularization, Pathologic; Plasminogen Activators | 2001 |
[Matrix metalloproteinase in human gastric carcinoma].
Topics: Biomarkers, Tumor; Hydroxamic Acids; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Neoplasm Invasiveness; Neoplasm Metastasis; Stomach Neoplasms; Tissue Inhibitor of Metalloproteinases | 2001 |
1 trial(s) available for marimastat and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hydroxamic Acids; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Probability; Proportional Hazards Models; Reference Values; Risk Assessment; Survival Analysis; Treatment Outcome | 2004 |
6 other study(ies) available for marimastat and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Multi-Domain Photopatterned 3D Tumor Constructs in a Micro-Physiological System for Analysis, Quantification, and Isolation of Infiltrating Cells.
Topics: Caco-2 Cells; Cell Separation; Colonic Neoplasms; Fluorouracil; HCT116 Cells; Humans; Hydrogels; Hydroxamic Acids; Lab-On-A-Chip Devices; Neoplasm Invasiveness; Neoplasm Metastasis | 2020 |
Cellular contractility and extracellular matrix stiffness regulate matrix metalloproteinase activity in pancreatic cancer cells.
Topics: Adenocarcinoma; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Shape; Collagen; Elasticity; Extracellular Matrix; Gels; Heparan Sulfate Proteoglycans; Heparin Lyase; Humans; Hydroxamic Acids; Matrix Metalloproteinases; Neoplasm Invasiveness; Neoplasm Proteins; Pancreatic Neoplasms; Recombinant Proteins | 2014 |
A chimeric antibody targeting CD147 inhibits hepatocellular carcinoma cell motility via FAK-PI3K-Akt-Girdin signaling pathway.
Topics: Animals; Antibodies; Antibody-Dependent Cell Cytotoxicity; Basigin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; CHO Cells; Cricetulus; Female; Focal Adhesion Kinase 1; Hep G2 Cells; Humans; Hydroxamic Acids; Immunoglobulin G; Immunoglobulin kappa-Chains; Liver Neoplasms; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Mice; Mice, Inbred BALB C; Microfilament Proteins; Neoplasm Invasiveness; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Pseudopodia; Recombinant Fusion Proteins; Signal Transduction; Single-Chain Antibodies; Stress Fibers; Vesicular Transport Proteins | 2015 |
Is British Biotech's Marimastat a major cancer drug?
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Industry; Enzyme Inhibitors; Humans; Hydroxamic Acids; Investments; Metalloendopeptidases; Neoplasm Invasiveness; Neoplasms; United Kingdom | 1996 |
Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro.
Topics: Animals; Brain; Cell Aggregation; Cell Division; Collagenases; Enzyme Inhibitors; Fetus; Gelatinases; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioma; Humans; Hydroxamic Acids; Matrix Metalloproteinase 2; Matrix Metalloproteinase 3; Matrix Metalloproteinase 7; Matrix Metalloproteinase 9; Metalloendopeptidases; Neoplasm Invasiveness; Neurons; Phenylalanine; Rats; Rats, Inbred Strains; Reverse Transcriptase Polymerase Chain Reaction; Thiophenes; Tumor Cells, Cultured; Urokinase-Type Plasminogen Activator | 1999 |
Specific expression of matrix metalloproteinases 1, 3, 9 and 13 associated with invasiveness of breast cancer cells in vitro.
Topics: Base Sequence; Basement Membrane; Breast Neoplasms; Collagen; DNA Primers; Drug Combinations; Enzyme-Linked Immunosorbent Assay; Hydroxamic Acids; Laminin; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Neoplasm Invasiveness; Proteoglycans; Reverse Transcriptase Polymerase Chain Reaction; Tissue Inhibitor of Metalloproteinases; Tumor Cells, Cultured | 2000 |